casticin and Neoplasms

casticin has been researched along with Neoplasms* in 4 studies

Reviews

3 review(s) available for casticin and Neoplasms

ArticleYear
An Overview of the Potential Antineoplastic Effects of Casticin.
    Molecules (Basel, Switzerland), 2020, Mar-12, Volume: 25, Issue:6

    Topics: Apoptosis; Caenorhabditis elegans Proteins; Cell Cycle Checkpoints; Cell Proliferation; Flavonoids; Forkhead Transcription Factors; Humans; Mitochondria; Neoplasms; Signal Transduction; STAT3 Transcription Factor

2020
Casticin from Vitex species: a short review on its anticancer and anti-inflammatory properties.
    Journal of integrative medicine, 2018, Volume: 16, Issue:3

    This short review provides an update of the anticancer and anti-inflammatory properties of casticin from Vitex species. Casticin is a polymethylflavone with three rings, an orthocatechol moiety, a double bond, two hydroxyl groups and four methoxyl groups. Casticin has been isolated from various tissues of plants in the Vitex genus: fruits and leaves of V. trifolia, aerial parts and seeds of V. agnus-castus and leaves of V. negundo. Studies have reported the antiproliferative and apoptotic activities of casticin from Vitex species. The compound is effective against many cancer cell lines via different molecular mechanisms. Studies have also affirmed the anti-inflammatory properties of casticin, with several molecular mechanisms identified. Other pharmacological properties include anti-asthmatic, tracheospasmolytic, analgesic, antihyperprolactinemia, immunomodulatory, opioidergic, oestrogenic, anti-angiogenic, antiglioma, lung injury protection, rheumatoid arthritis amelioration and liver fibrosis attenuation activities. Clinical trials and commercial use of the casticin-rich fruit extract of V. agnus-castus among women with premenstrual syndrome were briefly discussed.

    Topics: Animals; Anti-Inflammatory Agents; Flavonoids; Humans; Inflammation; Neoplasms; Plant Extracts; Vitex

2018
Molecular mechanisms of casticin action: an update on its antitumor functions.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:21

    Casticin (3', 5-dihydroxy-3, 4', 6, 7-tetramethoxyflavone) is an active compound isolated from roots, stems, leaves, fruits and seeds of a variety of plants. It is well known for its pharmacological properties and has been utilized as an anti-hyperprolactinemia, anti-tumor, anti-inflammatory, neuroprotetective, analgesic and immunomodulatory agent. Recently, the anticancer activity of casticin has been extensively investigated. The resulkts showed that it exerts protective potential by targeting apoptosis, considered important for cancer therapies. In this article, our aim was to review the pharmacological and therapeutic applications of casticin with specific emphasis on its anticancer functions and related molecular mechanisms. Chemotherapeutic effects are dependent on multiple molecular pathways, which may provide a new perspective of casticin as a candidate anti-neoplastic drug. This review suggests that additional studies and preclinical trials are required to determine specific intracellular sites of action and derivative targets in order to fully understand the mechanisms of its antitumor activity and validate this compound as a medicinal agent for the prevention and treatment of various cancers.

    Topics: Animals; Antineoplastic Agents; Flavonoids; Humans; Neoplasms

2014

Other Studies

1 other study(ies) available for casticin and Neoplasms

ArticleYear
The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action.
    Cancer letters, 2006, Oct-28, Volume: 242, Issue:2

    We studied the mechanism of anti-tumor activity of the flavonoid Casticin, derived from Achillea millefolium. Casticin anti-tumor activity results in cell growth arrest in G2/M and in apoptotic death. As a tubulin-binding agent (TBA), Casticin induces p21, which in turn inhibits Cdk1. Moreover, Casticin appears to down regulate cyclin A. These observations could explain Casticin-induced G2/M arrest. Following Casticin exposure, Bcl-2 depletion occurs in cancer cells, and a sub-G1 accumulation occurs in the cell cycle. Moreover, following a transient transfection with Bcl-2, MN1 cells are resistant to Casticin. A number of features suggest that Casticin could be important in cancer therapy. Indeed, Pgp over expressing cells are not resistant to Casticin, and its cell killing effect is observed even in p53 mutant or null cell lines.

    Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Flavonoids; Humans; Models, Chemical; Mutation; Neoplasms; Plant Extracts; Tetrazolium Salts; Thiazoles

2006